Iterum Therapeutics plc (ITRM)
$1.4
+0.01 (+0.72%)
Rating:
Recommendation:
-
| Symbol | ITRM |
|---|---|
| Price | $1.4 |
| Beta | 1.412 |
| Volume Avg. | 0.37M |
| Market Cap | 17.127M |
| Shares () | - |
| 52 Week Range | 0.601-7.05 |
| 1y Target Est | - |
| DCF Unlevered | ITRM DCF -> | |
|---|---|---|
| DCF Levered | ITRM LDCF -> | |
| ROE | -99.32% | Strong Sell |
| ROA | -60.83% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 119.84% | Buy |
| P/E | 10.77 | Strong Buy |
| P/B | 0.53 | Buy |
Latest ITRM news
About
Download (Excel)Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.